Next-Generation Protein Sequencing – CEOCFO Magazine Interview with Rapid Novor Inc

KITCHENER, Ontario, Aug. 22, 2017 /PRNewswire-iReach/ — Rapid Novor Inc, the world leader in the next-generation protein sequencing, today announces that Mingjie Xie, the CEO of Rapid Novor Inc, has been interviewed by CEOCFO Magazine’s Senior Editor Lynn Fosse.

The interview, included in the magazine’s recent August 21st issue, covers a range of topics from the company’s current monoclonal antibody sequencing service, the new mass spectrometry facility to the company’s strategies going forward. They also explored the differentiators against competitions and talked about the pros and cons comparing with the DNA sequencing based technology.

“We devoted ourselves to the development of the next-generation protein sequencing technologies and its application on antibody drug discovery and liquid biopsy.” said Mr. Xie in the interview. “Going forward and long term that is the value Rapid Novor Inc will provide.”

The full interview can be found at http://www.ceocfointerviews.com/interviews/RapidNovor17.htm.

About Rapid Novor Inc

Rapid Novor Inc is a privately held biotechnology company that develops the next-generation protein sequencing technologies and solutions. Specializing in the field of mass spectrometry-based proteomics, the company has developed the technology to directly sequence the antibody proteins without the needs to access the cell line. The company’s mission is to advance life science for better human health with next-generation protein sequencing. The company is headquartered in Kitchener, Ontario, Canada. For more information, visit www.rapidnovor.com.

Media Contact:Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.